Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors

In recent years, the incidence of various types of tumors has gradually increased, and it has also been found that there is a certain correlation between abnormal glucose and lipid metabolism and tumors. Glycolipid metabolism can promote tumor progression through multiple pathways, and the expressio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xianhu Zeng, Zhipeng Li, Chunrong Zhu, Lisa Xu, Yong Sun, Shangcong Han
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	targeted nano-drug carrier abnormal glucose and lipid metabolism gene carrier drugs tumors Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/14bb6a3ee1f946eeb3d445ba20ca82ca
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:14bb6a3ee1f946eeb3d445ba20ca82ca
record_format	dspace
spelling	oai:doaj.org-article:14bb6a3ee1f946eeb3d445ba20ca82ca2021-11-04T15:00:41ZResearch progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors1071-75441521-046410.1080/10717544.2021.1995081https://doaj.org/article/14bb6a3ee1f946eeb3d445ba20ca82ca2021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/10717544.2021.1995081https://doaj.org/toc/1071-7544https://doaj.org/toc/1521-0464In recent years, the incidence of various types of tumors has gradually increased, and it has also been found that there is a certain correlation between abnormal glucose and lipid metabolism and tumors. Glycolipid metabolism can promote tumor progression through multiple pathways, and the expression of related genes also directly or indirectly affects tumor metabolism, metastasis, invasion, and apoptosis. There has been much research on targeted drug delivery systems designed for abnormal glucose and lipid metabolism due to their accuracy and efficiency when used for tumor therapy. In addition, gene mutations have become an important factor in tumorigenesis. For this reason, gene therapy consisting of drugs designed for certain specifically expressed genes have been transfected into target cells to express or silence the corresponding proteins. Targeted gene drug vectors that achieve their corresponding therapeutic purposes are also rapidly developing. The genes related to glucose and lipid metabolism are considered as the target, and a corresponding gene drug carrier is constructed to influence and interfere with the expression of related genes, so as to block the tumorigenesis process and inhibit tumor growth. Designing drugs that target genes related to glucose and lipid metabolism within tumors is considered to be a promising strategy for the treatment of tumor diseases. This article summarizes the chemical drugs/gene drug delivery systems and the corresponding methods used in recent years for the treatment of abnormal glucose and lipid metabolism of tumors, and provides a theoretical basis for the development of glucolipid metabolism related therapeutic methods.Xianhu ZengZhipeng LiChunrong ZhuLisa XuYong SunShangcong HanTaylor & Francis Grouparticletargeted nano-drug carrierabnormal glucose and lipid metabolismgene carrier drugstumorsTherapeutics. PharmacologyRM1-950ENDrug Delivery, Vol 28, Iss 1, Pp 2329-2347 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	targeted nano-drug carrier abnormal glucose and lipid metabolism gene carrier drugs tumors Therapeutics. Pharmacology RM1-950
spellingShingle	targeted nano-drug carrier abnormal glucose and lipid metabolism gene carrier drugs tumors Therapeutics. Pharmacology RM1-950 Xianhu Zeng Zhipeng Li Chunrong Zhu Lisa Xu Yong Sun Shangcong Han Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors
description	In recent years, the incidence of various types of tumors has gradually increased, and it has also been found that there is a certain correlation between abnormal glucose and lipid metabolism and tumors. Glycolipid metabolism can promote tumor progression through multiple pathways, and the expression of related genes also directly or indirectly affects tumor metabolism, metastasis, invasion, and apoptosis. There has been much research on targeted drug delivery systems designed for abnormal glucose and lipid metabolism due to their accuracy and efficiency when used for tumor therapy. In addition, gene mutations have become an important factor in tumorigenesis. For this reason, gene therapy consisting of drugs designed for certain specifically expressed genes have been transfected into target cells to express or silence the corresponding proteins. Targeted gene drug vectors that achieve their corresponding therapeutic purposes are also rapidly developing. The genes related to glucose and lipid metabolism are considered as the target, and a corresponding gene drug carrier is constructed to influence and interfere with the expression of related genes, so as to block the tumorigenesis process and inhibit tumor growth. Designing drugs that target genes related to glucose and lipid metabolism within tumors is considered to be a promising strategy for the treatment of tumor diseases. This article summarizes the chemical drugs/gene drug delivery systems and the corresponding methods used in recent years for the treatment of abnormal glucose and lipid metabolism of tumors, and provides a theoretical basis for the development of glucolipid metabolism related therapeutic methods.
format	article
author	Xianhu Zeng Zhipeng Li Chunrong Zhu Lisa Xu Yong Sun Shangcong Han
author_facet	Xianhu Zeng Zhipeng Li Chunrong Zhu Lisa Xu Yong Sun Shangcong Han
author_sort	Xianhu Zeng
title	Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors
title_short	Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors
title_full	Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors
title_fullStr	Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors
title_full_unstemmed	Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors
title_sort	research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/14bb6a3ee1f946eeb3d445ba20ca82ca
work_keys_str_mv	AT xianhuzeng researchprogressofnanocarriersforgenetherapytargetingabnormalglucoseandlipidmetabolismintumors AT zhipengli researchprogressofnanocarriersforgenetherapytargetingabnormalglucoseandlipidmetabolismintumors AT chunrongzhu researchprogressofnanocarriersforgenetherapytargetingabnormalglucoseandlipidmetabolismintumors AT lisaxu researchprogressofnanocarriersforgenetherapytargetingabnormalglucoseandlipidmetabolismintumors AT yongsun researchprogressofnanocarriersforgenetherapytargetingabnormalglucoseandlipidmetabolismintumors AT shangconghan researchprogressofnanocarriersforgenetherapytargetingabnormalglucoseandlipidmetabolismintumors
_version_	1718444756743225344

Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors

Ejemplares similares